These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 6429891)

  • 1. Factor VIII inhibitor treatment with high doses of F VIII.
    Stenbjerg S; Ingerslev J; Zachariae E
    Thromb Res; 1984 Jun; 34(6):533-9. PubMed ID: 6429891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of immune responses following 102 infusions of autoplex in 18 hemophilic patients with antibody to factor VIII.
    Laurian Y; Girma JP; Lambert T; Meyer D; Larrieu MJ
    Blood; 1984 Feb; 63(2):457-62. PubMed ID: 6419798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Improvement in anti-hemophilic preparations and its problems. 3. Treatment of hemophilia patients with inhibitors; induction of immune tolerance by a low or intermediate dose regimen].
    Iizuka A
    Rinsho Ketsueki; 1988 May; 29(5):640-8. PubMed ID: 3145995
    [No Abstract]   [Full Text] [Related]  

  • 4. Apheresis.
    Nilsson IM; Freiburghaus C
    Adv Exp Med Biol; 1995; 386():175-84. PubMed ID: 8851026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune tolerance by intermittent factor VIII boluses in two high responder hemophilia A patients.
    Landolfi R; de Cristofaro R; Lazzareschi I; Riccardi R; Mariani G
    Haematologica; 2000 Oct; 85(10 Suppl):73-4. PubMed ID: 11187877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII.
    Sultan Y; White GC; Aronstam A; Bosser C; Brackmann HH; Brochier G; Gormsen J; Mariani G; Roberts HR; Scarabin Y
    Nouv Rev Fr Hematol (1978); 1986; 28(2):85-9. PubMed ID: 3090516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preliminary experience with achieving immune tolerance in patients with hemophilia A and circulating factor VIII inhibitor].
    Scharf R; Kucharski W; Lopaciuk S; Celińska W; Dmytrow A; Domański K; Gonet S; Miastkowski Z; Nowakowska I; Przybylski A
    Acta Haematol Pol; 1991; 22(1):92-9. PubMed ID: 1823972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of immuninhibitor hemophilia A with FEIBA plasma fraction].
    István L; Bariska I; Marton E
    Orv Hetil; 1980 Dec; 121(51):3131-5. PubMed ID: 6784062
    [No Abstract]   [Full Text] [Related]  

  • 10. [The occurrence of immunological tolerance to inhibitors of factors VIII and IX in hemophilia patients].
    Brakman GG
    Gematol Transfuziol; 1993 Feb; 38(2):18-20. PubMed ID: 8020714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regimens of factor VIII administration--continuous infusion vs. bolus.
    Berntorp E
    Haematologica; 2000 Oct; 85(10 Suppl):69-71; discussion 71-2. PubMed ID: 11187875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
    Zwahlen H; Beck EA
    Acta Haematol; 1980; 64(1):12-7. PubMed ID: 6774572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.
    Nilsson IM; Berntorp E; Zettervall O
    N Engl J Med; 1988 Apr; 318(15):947-50. PubMed ID: 3127711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)].
    Verroust F; Moussard C; Allain JP
    Presse Med; 1985 May; 14(19):1073-6. PubMed ID: 3158962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hemophiliacs with inhibitors].
    Fujimaki M
    Rinsho Ketsueki; 1985 Jul; 26(7):1059-68. PubMed ID: 3932719
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of activated prothrombin complex concentrates in a hemophiliac with an anti-factor VIII antibody.
    Blatt PM; White GC; McMillan CW; Webster WP
    JAMA; 1984 Jan; 251(1):67. PubMed ID: 6418898
    [No Abstract]   [Full Text] [Related]  

  • 18. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose.
    Van Leeuwen EF; Mauser-Bunschoten EP; Van Dijken PJ; Kok AJ; Sjamsoedin-Visser EJ; Sixma JJ
    Br J Haematol; 1986 Oct; 64(2):291-7. PubMed ID: 3096366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members.
    DiMichele DM; Kroner BL
    Vox Sang; 1999; 77 Suppl 1():31-2. PubMed ID: 10529684
    [No Abstract]   [Full Text] [Related]  

  • 20. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    DiMichele D; Kroner B;
    Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.